Sara Quist

Search results

• 2025

  A cost-minimization analysis of anti-VEGFs for the treatment of neovascular age-related macular degeneration in the Netherlands

  Quist, S. W., Nab, H., Postma, M., Amarakoon, S., van Asten, F. & Freriks, R., Feb-2025, In: Graefe's Archive for Clinical and Experimental Ophthalmology. 263, p. 327–345 19 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Faricimab 100%
  • Flexible Extended Regimen 91%
  • Neovascular AMD 45%
  • Net Price 45%
  2 Downloads (Pure)
• 2024

  Cost-effectiveness of hydroxychloroquine retinopathy screening: the current guideline versus no screening and reduced regimens

  Quist, S. W., Dorsthorst, S. T., Freriks, R. D., Postma, M. J., Hoyng, C. B. & van Asten, F., 20-Aug-2024, (E-pub ahead of print) In: European Journal of Health Economics. 13 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Practice Guideline 100%
  • Cost Effectiveness Analysis 100%
  • Retinopathy 100%
  • Hydroxychloroquine 100%
  • Quality Adjusted Life Year 100%
  3 Downloads (Pure)
• 2023

  Cost-effectiveness of finerenone in chronic kidney disease associated with type 2 diabetes in The Netherlands

  Quist, S. W., van Schoonhoven, A. V., Bakker, S. J. L., Pochopień, M., Postma, M. J., van Loon, J. M. T. & Paulissen, J. H. J., Dec-2023, In: Cardiovascular Diabetology. 22, 1, 16 p., 328.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Netherlands 100%
  • Type 2 Diabetes Mellitus (T2DM) 100%
  • Standard of Care 100%
  • Cost-effectiveness 100%
  • Disease-associated 100%
  9 Citations (Scopus)

  108 Downloads (Pure)

• Cost-effectiveness of ravulizumab compared with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria in the Netherlands

  Quist, S. W., Postma, A. J., Myrén, K. J., de Jong, L. A. & Postma, M. J., 2023, In: European Journal of Health Economics. 18 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Health Care Cost 100%
  • Cost-Effectiveness Analysis 100%
  • Eculizumab 100%
  • Paroxysmal Nocturnal Hemoglobinuria 100%
  • Ravulizumab 100%
  4 Citations (Scopus)

  175 Downloads (Pure)

• Costs of radium-223 and the pharmacy preparation ¹⁷⁷Lu-PSMA-I&T for metastatic castration-resistant prostate cancer in Dutch hospitals

  Quist, S. W., Paulissen, J. H. J., Wyndaele, D. N. J., Nagarajah, J. & Freriks, R. D., 1-Mar-2023, In: Journal of Medical Economics. 26, 1, p. 366-375 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access

  File

  • Lutetium 177 100%
  • Castration Resistant Prostate Cancer 100%
  • Radiopharmaceutical Agent 44%
  • Clinical Trial 11%
  • Overall Survival 11%
  3 Citations (Scopus)

  343 Downloads (Pure)